scPharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

scPharmaceuticals (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2018, and provided a business update.

As quoted in the press release:

“Our first full quarter as a public company was very productive and set the foundation for what we believe will be a transformational year for scPharmaceuticals,” said John Tucker, president and chief executive officer of scPharmaceuticals. “With the approaching PDUFA date for FUROSCIX, we are preparing for the potential commercial launch early in the fourth quarter of 2018. In addition to expanding our team with key hires to help plan and execute our commercial strategy, we continue to work with investigators to advance clinical studies to further support the economic and clinical value of FUROSCIX.”

Click here to read the full press release.